EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review

Liana Iordan, Laura Gaita iD, Romulus Timar, Vlad Avram, Adrian Sturza, Bogdan Timar iD

International Journal of Molecular Sciences · 27.06.2024 · 25 (13) · 7057

DOI: 10.3390/ijms25137057 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.06.2024. Verfasst von Liana Iordan und 5 weiteren Autor:innen. Beteiligte Einrichtung: "Pius Brinzeu" Emergency County Hospital, 300723 Timisoara, Romania. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 237 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Victor Babes” University of Medicine and Pharmacy Timisoara, Romania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) is a noncommunicable condition that has become a major healthcare burden across the globe, often underdiagnosed and associated with low awareness. The main cause that leads to the development of renal impairment is diabetes mellitus and, in contrast to other chronic complications such as retinopathy or neuropathy, it has been suggested that intensive glycemic control is not sufficient in preventing the development of diabetic kidney disease. Nevertheless, a novel class of antidiabetic agents, the sodium-glucose cotransporter-2 inhibitors (SGLT2i), have shown multiple renoprotective properties that range from metabolic and hemodynamic to direct renal effects, with a major impact on reducing the risk of occurrence and progression of CKD. Thus, this review aims to summarize current knowledge regarding the renoprotective mechanisms of SGLT2i and to offer a new perspective on this innovative class of antihyperglycemic drugs with proven pleiotropic beneficial effects that, after decades of no significant progress in the prevention and in delaying the decline of renal function, start a new era in the management of patients with CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicHumansAnimalsKidneyDiabetic NephropathiesDiabetes Mellitus, Type 2Hypoglycemic AgentsSodium-Glucose Transporter 2

Stichwörter der Autor:innen

SGLT2ichronic kidney diseasepreventionrenoprotectiontype 2 diabetes mellitus

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic AgentsSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • "Pius Brinzeu" Emergency County Hospital, 300723 Timisoara, Romania.
  • Second Department of Internal Medicine, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
  • Department of Functional Sciences, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.

ORCID-Profile: Laura Gaita, Bogdan Timar

Förderung

  • “Victor Babes” University of Medicine and Pharmacy Timisoara, Romania

Zitieren

APA

Iordan, L., Gaita, L., Timar, R., Avram, V., Sturza, A., & Timar, B. (2024). The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review. International Journal of Molecular Sciences, 25(13), 7057. https://doi.org/10.3390/ijms25137057

Vancouver

Iordan L, Gaita L, Timar R, Avram V, Sturza A, Timar B. The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review. International Journal of Molecular Sciences. 2024;25(13):7057. doi:10.3390/ijms25137057

BibTeX
@article{Iordan2024,
  author = {Iordan, Liana and Gaita, Laura and Timar, Romulus and Avram, Vlad and Sturza, Adrian and Timar, Bogdan},
  title = {The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {13},
  pages = {7057},
  doi = {10.3390/ijms25137057}
}
Kostenlos starten →